Market Newsdesk

CACI Names Glenn Kurowski Chief Technology Officer

Kurowski to advance critical technologies to mission and enterprise customers

ARLINGTON, Va.–(BUSINESS WIRE)–
CACI International Inc (NYSE: CACI) announced today that it has named Glenn Kurowski Chief Technology Officer (CTO) to advance critical technologies, drive technology investments, and recruit and develop the company’s technical workforce to accelerate growth and innovatively address its mission and enterprise customers’ most challenging needs.

As CTO, Kurowski will work across the company to lead corporate technology outreach and help realize CACI’s technical vision, its investments for growth in national security technology, as well as to continue building the company’s scientific, engineering, and technical talent. A veteran of the government contracting industry, and a proven innovator and strategist, Kurowski has served with CACI for more than six years and was instrumental in shaping the company’s transition to a technology-powered national security leader. Additionally, Kurowski has worked across CACI to leverage its scientists, innovators, and technical talent to create innovative solutions for CACI’s mission and enterprise customers and generate new intellectual property and product offerings.

CACI invests ahead of customer needs to help them maintain a technological edge. The company’s active research and development has driven key advances and award-winning technologies in the areas of Electronic Warfare, Counter-Unmanned Aerial Systems, Cybersecurity, Signals Intelligence, Agile Software Development at scale, Artificial Intelligence, and Secure Communications. Most recently, CACI’s SteelBox™, a secure mobile communications app, and the CACI CM142 sensor, which delivers real-time intelligence to aerial firefighters, each earned an acclaimed Edison Award™ for their excellence in technological innovation.

John Mengucci, CACI President and Chief Executive Officer, said, “Glenn’s knowledge and experience in guiding differentiated technologies from idea to the field, makes him the perfect individual to ensure our customers can best execute their missions, as well as drive long-term value for our shareholders.”

CACI’s approximately 23,000 talented employees are vigilant in providing the unique expertise and distinctive technology that address our customers’ greatest enterprise and mission challenges. Our culture of good character, innovation, and excellence drives our success and earns us recognition as a Fortune World’s Most Admired Company. As a member of the Fortune 1000 Largest Companies, the Russell 1000 Index, and the S&P MidCap 400 Index, we consistently deliver strong shareholder value. Visit us at www.caci.com.

There are statements made herein which do not address historical facts, and therefore could be interpreted to be forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to factors that could cause actual results to differ materially from anticipated results. The factors that could cause actual results to differ materially from those anticipated include, but are not limited to, the risk factors set forth in CACI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020, and other such filings that CACI makes with the Securities and Exchange Commission from time to time. Any forward-looking statements should not be unduly relied upon and only speak as of the date hereof.

CACI-Company News

View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005056/en/

Corporate Communications and Media:

Jody Brown, Executive Vice President, Public Relations

(703) 841-7801, [email protected]

Investor Relations:

Daniel Leckburg, Senior Vice President, Investor Relations

(703) 841-7666, [email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Technology Other Defense Contracts Aerospace Manufacturing Software Networks Data Management Defense

MEDIA:

Logo

Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting

REQORSA Enhances Efficacy of Chemo-Immune Combination Therapy in KRAS-LKB1 Mutant NSCLC in Humanized Mice

REQORSA Overcomes Resistance to Targeted Therapy Osimertinib

AUSTIN, Texas–(BUSINESS WIRE)–Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for the combination of TUSC2 immunogene therapy (REQORSA™) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC). Collaborators also presented positive preclinical data for the use of REQORSA in combination with targeted therapies for the treatment of NSCLC. These data were presented in two presentations at the 2021 American Association of Cancer Research (AACR) annual meeting. The TUSC2 gene is a tumor suppressor gene and is the active agent in REQORSA.

“We are pleased to have these positive data that provide further support for the therapeutic potential of REQORSA in combination with immunotherapies and targeted therapies in NSCLC presented before an audience of the world’s leading cancer researchers. These data are particularly encouraging as we look to initiate our upcoming combination Acclaim-1 and Acclaim-2 clinical trials of REQORSA in NSCLC,” said Rodney Varner, President and Chief Executive Officer of Genprex. “We know that many patients inevitably develop resistance to immune checkpoint blockade therapy or EGFR-TKI therapy. These data show that REQORSA in combination with immunotherapies and targeted therapies may provide enhanced efficacy in NSCLC that has become resistant to these regimens, offering hope to a large patient population who currently has limited treatment options.”

Featured Genprex-supported posters presented at AACR 21 include:

Oral Presentation
Session:						MS.IM02.02 – Overcoming Resistance in the Tumor Microenvironment: Novel Immunomodulatory Agents
Title:						“TUSC2 immunogene therapy enhances efficacy of chemo-immune combination therapy and induces robust antitumor immunity in KRAS-LKB1 mutant NSCLC in humanized mice”
Poster Number/Channel:						#76/Channel 03
Presentation Date/Time:						April 10, 2021 from 2:50-3:00 p.m. ET
Presenters:						Ismail M. Meraz, Mourad Majidi, RuPing Shao, Feng Meng, Min Jin Ha, Elizabeth Shpall, Jack A. Roth. University of Texas MD Anderson Cancer Center, Houston, TX
Poster Presentation
Session:						PO.ET03.01 – Drug Resistance in Molecular Targeted Therapies
Title:						“Overcoming resistance to osimertinib by TUSC2 gene therapy in EGFR mutant NSCLC”
Poster Number:						#1105
Presentation Date/Time:						April 10, 2021 from 8:30 a.m. – 11:59 p.m. ET
Presenters:						Ismail M. Meraz, Mourad Majidi, RuPing Shao, Lihui Gao, Meng Feng, Huiqin Chen, Min Jin Ha, Jack A

The first presentation, entitled “TUSC2 immunogene therapy enhances efficacy of chemo-immune combination therapy and induces robust antitumor immunity in KRAS-LKB1 mutant NSCLC in humanized mice,” showed that the triple combination of chemotherapy, immunotherapy (immune checkpoint blockade) and REQORSA demonstrated strong antitumor efficacy and induced robust antitumor immunity in KRAS-LKB1 (KL)-mutant NSCLC in clinically relevant humanized mice models.

In this study, researchers evaluated the antitumor immune response of a chemo-immunotherapy combination with REQORSA on highly metastatic KL-mutant human lung cancer in humanized mice. Humanized mice were first treated with REQORSA, immunotherapy nivolumab (Opdivo®), or the combination. The results showed synergistic antitumor activity with the combination. Next, humanized mice were treated with REQORSA, immunotherapy pembrolizumab (Keytruda®), or the combination. When REQORSA was added to the chemotherapy and immune checkpoint blockade combination, metastases regression was significantly greater than either REQORSA, REQORSA and pembrolizumab, or chemotherapy and pembrolizumab treatments.

“KRAS is a frequent genomic driver in lung adenocarcinoma,” said Michael Redman, Executive Vice President and Chief Operating Officer of Genprex. “LKB1 (also known as STK11) is a distinct subgroup of KRAS-mutants and is the most prevalent genomic driver of resistance to PD-1 blockade in KRAS-mutant lung cancer.”

The second poster, entitled “Overcoming resistance to osimertinib by TUSC2 gene therapy in EGFR-mutant NSCLC,” showed that REQORSA in combination with targeted therapy osimertinib (Tagrisso®) demonstrated synergistic antitumor efficacy in EGFR mutant osimertinib resistant NSCLC tumors in H1975-OsiR isogenic tumors. Researchers also found that the upregulation of PDK1 was associated with osimertinib resistance.

In this study, researchers developed an osimertinib resistant H1975-OsiR isogenic cell line through continuous exposure to osimertinib. Xenograft tumors from both H1975-parental and H1975-OsiR cells were developed in NSG mice and were treated with osimertinib. Synergistic antitumor activity of REQORSA and osimertinib was found in H1975-OsiR tumors. The combinations showed a robust antitumor effect compared with single agent treatment groups. Reverse phase protein array (RPPA) data showed that PDK1 was significantly upregulated in the REQORSA and osimertinib group when compared with either control, osimertinib alone or REQORSA alone treated H1975-OsiR tumors, indicating that PDK1 may be associated with osimertinib resistance. No PDK1 inhibitor effect was found in the REQORSA treated group, implicating the specific role of PDK1 in osimertinib resistance.

These AACR presentations and posters have been made available on Genprex’s website at www.genprex.com.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EGFR mutations whose tumors progressed after treatment with osimertinib alone.

The Company is preparing to initiate its Acclaim-1 and Acclaim-2 clinical trials for the treatment of NSCLC. Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial that combines REQORSA with AstraZeneca’s Tagrisso in patients with late-stage NSCLC with mutated epidermal growth factor receptors (EGFRs), whose disease progressed after treatment with Tagrisso. The Acclaim-2 clinical trial will combine REQORSA with Merck & Co’s Keytruda for NSCLC patients who are low expressors (1% to 49%) of the protein programmed death-ligand 1 (PD-L1).

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex’s intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005055/en/

Genprex, Inc.

(877) 774-GNPX (4679)

Investor Relations

GNPX Investor Relations

(877) 774-GNPX (4679) ext. #2

[email protected]

Media Contact

Genprex Media Relations

Kalyn Dabbs

(877) 774-GNPX (4679) ext. #3

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Science Biotechnology Research Pharmaceutical Oncology Health Genetics Clinical Trials

MEDIA:

Logo

Applebee’s® Brings Flavor to the Neighborhood with the Return of Irresist-A-Bowls

Guest-favorite Irresist-A-Bowls™ are BACK for just $8.99

GLENDALE, Calif.–(BUSINESS WIRE)–
Applebee’s Irresist-A-Bowls are making their return, and they’re better than ever. Now and for a limited time, guests can enjoy their favorite bowls packed with mouthwatering ingredients. Available for Dine-In, To Go or Delivery, each bowl is overflowing with delicious flavor you won’t be able to resist … all for only $8.99!*

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005020/en/

Each of Applebee’s Irresist-A-Bowls come with abundant toppings and are served up in delicious flavor combinations you can’t get anywhere else. Get adventurous and try the NEW Grilled Chicken & Spinach Alfredo Bowl or celebrate the return of our Crispy Orange Chicken Bowl. There’s no going wrong with this menu:

• NEW Grilled Chicken & Spinach Alfredo Bowl
• Homestyle Chicken Bowl
• Crispy Orange Chicken Bowl
  • Guests can substitute shrimp for chicken at no cost
• Tex-Mex Shrimp Bowl
• Southwest Chicken Bowl
  • Guests can add steak for just $2

“When Applebee’s re-introduced Irresist-A-Bowls last year, guests were very excited about the combination of fresh new flavors at a tasty price,” said Joel Yashinsky, Chief Marketing Officer at Applebee’s. “Now, we are bringing more new flavors and favorites that give guests even more reasons to visit our restaurants or enjoy at home.”

For local restaurant hours, visit Applebees.com/restaurants, or to order Applebee’s for To Go or Delivery, visit Applebees.com or the Applebee’s mobile app (iOS, Google). Details on Applebee’s safety-first dining experience can be found at Applebees.com/safety.

For even more exclusive deals and specials, guests can sign-up to be a part of the neighborhood. Join Applebee’s E-Club and receive a welcome offer!

*Limited time. Price, participation, and selection may vary. Offer may not be valid with other offers, discounts or promotions. While supplies last. Delivery coverage varies by restaurant location.

About Applebee’s®

As one of the world’s largest casual dining brands, Applebee’s Neighborhood Grill + Bar serves as America’s kitchen table, offering guests a lively dining experience that combines simple, craveable American fare with classic drinks and local drafts. Applebee’s restaurants are owned and operated by entrepreneurs dedicated to more than serving great food, but also building up the communities that we call home. From raising money for local charities to hosting community fundraisers, Applebee’s is always Doin’ Good in the Neighborhood®. Applebee’s has 1,711 franchise and company-operated restaurants in the United States, Puerto Rico, Guam and 11 other countries as of December 31, 2020. Applebee’s is franchised by subsidiaries of Dine Brands Global Inc. [NYSE: DIN], which is one of the world’s largest full-service restaurant companies.

Follow us:

Instagram: @applebees

Twitter: @applebees

Facebook: www.facebook.com/applebees

For media inquiries, email us at [email protected]

View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005020/en/

Applebee’s

Melissa Hariri

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Retail Restaurant/Bar Food/Beverage

MEDIA:

Logo

Photo

Applebee’s® Brings Flavor to the Neighborhood with the Return of Irresist-A-Bowls (Photo: Business Wire)

Rayonier Advanced Materials Announces Strategic Sale of its Lumber and Newsprint Businesses to GreenFirst Forest Products for approximately $214 million

JACKSONVILLE, Fla. & VANCOUVER, British Columbia–(BUSINESS WIRE)–
Rayonier Advanced Materials Inc. (NYSE: RYAM) (“RYAM”), a global leader in high purity cellulose pulp, and GreenFirst Forest Products Inc. (TSXV: GFP) (“GreenFirst”), a Canadian lumber company, announced today that the parties have entered into a binding asset purchase agreement (the “Agreement”) pursuant to which RYAM has agreed to sell all of its lumber and newsprint facilities and related assets located in Ontario and Québec. (the “Purchased Assets”) to GreenFirst for an expected purchase price of approximately US$214 million including inventory on hand at the time of closing (the “Purchase Price”) which is payable approximately 85% in cash, 15% common shares of the capital of GreenFirst. In addition, a chip offset credit note will be issued to RYAM by GreenFirst in the amount of CDN$7.9 million, which may be set off against amounts owing to GreenFirst for chip purchases, equally over the next 5 years. Notably, RYAM will retain all of the cash generated by the Purchased Assets plus all softwood lumber duties, including earned interest on the duties, paid to the U.S. Department of Commerce through the closing date. RYAM estimates the duties to be approximately $110 million at the time of closing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005334/en/

The Purchased Assets:

• include six lumber mills which are located in Chapleau, Cochrane, Hearst and Kapuskasing in Ontario and in Béarn and La Sarre in Québec as well as one newsprint mill located in Kapuskasing, Ontario.
• produced 604 million board feet in 2020 with a combined nameplate capacity of 755 million board feet and are capable of producing a wide range of forest products used in residential and commercial construction, including dimensional lumber, wood chips and by-products.
• include the lumber and newsprint mills as well as certain real property, machinery, inventory, permits, licenses and other related assets.
• exclude accounts receivable and accounts payable.

RYAM and GreenFirst have also agreed to a 20-year residual fiber supply agreement to meet the continued fiber sourcing needs of RYAM’s High Purity Cellulose, High Yield and Paperboard operations in Temiscaming, Québec. The closing of the Agreement, which is expected to occur in the second half of 2021, but not prior to July 31, is subject to customary closing conditions, including receipt of regulatory approvals, the transfer of forestry licenses and the approval of the TSX Venture Exchange.

“This is a tremendous opportunity,” said Paul Rivett, Incoming Chairman of GreenFirst Forest Products and Chairman of NordStar Capital. “This represents a large step forward to our previously announced strategy of building GreenFirst as focused on lumber, newsprint and forestry investments. We are excited to be expanding our manufacturing footprint through this investment and to beginning a new chapter with all of Rayonier Advanced Materials’ sawmill and forestry employees in Ontario and Québec.”

“The sale of the lumber and newsprint businesses allows us to divest non-core assets at an attractive valuation and positions Rayonier Advanced Materials to further invest in the earnings growth of our core High Purity Cellulose assets and its biofuture while also reducing overall debt. Through our ongoing ownership in GreenFirst, we expect to participate in further upside while maintaining optionality to monetize at an appropriate time,” said Paul G. Boynton, President and Chief Executive Officer of Rayonier Advanced Materials. “I want to personally thank the lumber and newsprint management team and employees for their dedicated work for Rayonier Advanced Materials. We wish them well as they begin a new chapter with GreenFirst.”

For Rayonier Advanced Materials, BofA Securities is serving as financial advisor and McCarthy Tétrault LLP is serving as legal counsel. For GreenFirst, RBC Capital Markets is serving as financial advisor, NordStar Capital is serving as transactional advisor, Norton Rose Fulbright Canada LLP is serving as legal counsel and KPMG Transaction Services assisted with due diligence.

GreenFirst shareholders are directed to GreenFirst’s standalone press release issued today, which provides additional operational and financial information concerning the transaction.

About Rayonier Advanced Materials

Rayonier Advanced Materials is a global leader of cellulose-based technologies, including high purity cellulose specialties, a natural polymer commonly found in filters, food, pharmaceuticals and other industrial applications. The Company also manufactures products for lumber, paper and packaging markets. With manufacturing operations in the U.S., Canada and France, Rayonier Advanced Materials employs approximately 4,000 people and generates approximately $1.7 billion of revenues. More information is available at www.rayonieram.com.

About GreenFirst Forest Products

GreenFirst is a forest-first business, focused on environmentally sustainable forest management and lumber production. We believe that sustainable forest planting and harvesting, coupled with the long-term green advantage of lumber, provide GreenFirst with significant cyclical and secular advantages in building products. GreenFirst’s long-term pursuit is to be a global leader in environmentally sustainable lumber. For more information, please visit: www.gffp.ca

Forward-Looking Statements

Certain statements in this press release may constitute forward-looking statements that reflect management’s expectations regarding GreenFirst’s and Rayonier Advanced Materials’ future growth, financial performance and business prospects and opportunities, including in respect of the proposed transaction, as of the date of this press release. For example, this release includes, among others, forward-looking statements regarding GreenFirst’s and Rayonier Advanced Materials’ expectations regarding the anticipated benefits of the transaction; the future performance of the underlying businesses; the impact of the transaction on GreenFirst and its business; the anticipated receipt of required regulatory approvals; and the anticipated timing for closing the transaction. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “anticipate”, “believe”, “plan”, “forecast”, “expect”, “estimate”, “predict”, “intend”, “would”, “could”, “if”, “may” and similar expressions. However, the absence of these or similar words or expressions does not mean a statement is not forward-looking.

All such statements are made pursuant to the “safe harbour” provisions of applicable Canadian securities legislation as well as the “safe harbor” provisions of applicable U.S. securities law, including without limitation the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements reflect current expectations of management regarding future events and operating performance and speak only as of the date of this press release. In addition, forward-looking statements are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes.

By their nature, forward-looking statements require management to make assumptions and are subject to inherent risks and uncertainties. There is a significant risk that predictions, forecasts, conclusions or projections will not prove to be accurate, that management’s assumptions may not be accurate and that actual results, performance or achievements may differ significantly from such predictions, forecasts, conclusions or projections expressed or implied by such forward-looking statements. We caution readers not to place undue reliance on the forward-looking statements in this press release as a number of factors could cause actual future results, conditions, actions or events to differ materially from the targets, outlooks, expectations, goals, estimates or intentions expressed in the forward-looking statements.

These factors include, but are not limited to: general global economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; relationships with employees, customers, business partners and competitors; and diversion of management time on the transaction. There are also risks that are inherent in the nature of the transaction, including failure to satisfy the conditions to the completion of the transaction and failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for completion of the transaction may change for a number of reasons, including the inability to secure necessary regulatory or other approvals in the time assumed or the need for additional time to satisfy the conditions to the completion of the transaction. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of the transaction.

GreenFirst and Rayonier Advanced Materials caution that the foregoing list is not exhaustive of all possible factors, as other factors could adversely affect our results.

When relying on forward-looking statements to make decisions with respect to GreenFirst, Rayonier Advanced Materials and their securities, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Neither GreenFirst and Rayonier Advanced Materials do not intend, and disclaim any obligation, to update any forward-looking statements, whether written or oral, or whether as a result of new information or otherwise, except as may be required by law.

Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005334/en/

RYAM Media

Ryan Houck

904-357-9134

RYAM Investors

Mickey Walsh

904-357-9162

GFP Media & Investors

Jonathan Lowenstein

416-642-6430

KEYWORDS: United States North America Canada Florida

INDUSTRY KEYWORDS: Engineering Other Natural Resources Forest Products Manufacturing Natural Resources Other Manufacturing

MEDIA:

Logo

Logo

Yvette Butler joins Voya Financial board of directors

NEW YORK–(BUSINESS WIRE)–
Voya Financial, Inc. (NYSE: VOYA), announced today that Yvette Butler, 55, president, SVB Private Bank & Wealth Management, has joined the company’s board of directors. She will serve on the compensation and benefits committee; the nominating and governance committee; and the risk, investment and finance committee.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005534/en/

“I am very pleased to welcome Yvette to the Voya board,” said Rodney O. Martin, Jr., chairman and chief executive officer. “Yvette brings to our board over 25 years of experience in financial services, where she has distinguished herself as a strategist and leader in providing wealth advisory, banking and financial planning solutions. In particular, Yvette’s expertise in strategy development, operational execution, compliance and risk, digital product management and disruptive technologies will benefit all of our stakeholders. Her insights will be extremely valuable as we work to create a better financial future for all.”

Prior to joining SVB in June 2018, Butler served as executive vice president of Capital One Investing since April 2013. Before joining Capital One, she was managing director for Wells Fargo Advisors, heading up the direct business teams, including WFA Solutions and WellsTrade. Butler also previously led investor marketing for E*Trade and, at Merrill Lynch, launched the firm’s financial advisory center, which later became Merrill Edge. Butler’s early career included roles at Charles Schwab and McKinsey & Company.

Butler was named to the Washingtonian’s prestigious list of Most Powerful Women in Washington in 2017 and was named to Savoy magazine’s 100 Most Influential Blacks in Corporate America in 2020. She received an MBA from Stanford University’s Graduate School of Business and a bachelor’s degree in finance and management information systems from the University of Virginia’s McIntire School of Commerce. She is a board member and treasurer of the Washington Area Women’s Foundation.

About Voya Financial^®

Voya Financial, Inc. (NYSE: VOYA), provides health, wealth and investment solutions that enable its approximately 14.8 million individual, workplace and institutional clients to achieve their financial wellness goals with confidence. With a vision to be America’s Retirement Company^®, Voya’s products, solutions and digital capabilities help create a better financial future for all. Voya is a Fortune 500 company that had $7.6 billion in revenue in 2020 and $700 billion in total assets under management and administration as of Dec. 31, 2020. Certified as a “Great Place to Work” by the Great Place to Work^® Institute, Voya is equally committed to conducting business in a way that is socially, environmentally, economically and ethically responsible. Voya has earned recognition as one of the World’s Most Ethical Companies^® by the Ethisphere Institute; as the No. 1-ranked financial services firm among Barron’s 100 Most Sustainable Companies for three consecutive years; as a member of the Bloomberg Gender-Equality Index; and as a “Best Place to Work for Disability Inclusion” on the Disability Equality Index. For more information, visit voya.com. Follow Voya Financial on Facebook, LinkedIn and Twitter @Voya.

VOYA-IR VOYA-CF

View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005534/en/

Media Contact:

Christopher Breslin
(212) 309-8941

[email protected]

Investor Contact:

Michael Katz

(212) 309-8999

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Other Professional Services Insurance Finance Consulting Banking

MEDIA:

Logo

Photo

Yvette Butler, president, SVB Private Bank & Wealth Management, has joined the Voya Financial, Inc. (NYSE: VOYA) board of directors. (Photo: Business Wire)